ACE Inhibitors: Nutrient Depletions Guide

ACE (angiotensin-converting enzyme) inhibitors represent one of the most widely prescribed cardiovascular medication classes globally, with approximately 55 million prescriptions dispensed annually in the United States for lisinopril alone. These medications function by blocking the angiotensin-converting enzyme, which prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that raises blood pressure and increases cardiac workload. By inhibiting this critical enzyme, ACE inhibitors help blood vessels relax, reduce blood pressure, and protect vital organs including the heart and kidneys. According to the CTD database, this drug class demonstrates 17 chemical-gene interactions across the class, with [lisinopril](/medications/lisinopril) specifically showing interactions with 24 genes including ACE, ACE2, and AGT. The FAERS database contains 181,237 reports for lisinopril alone, reflecting the extensive real-world use and safety monitoring of these medications. First introduced in the 1980s, ACE inhibitors revolutionized cardiovascular medicine by providing the first targeted approach to blocking the renin-angiotensin system. PubMed analysis reveals 237 randomized controlled trials involving 240,147 patients, establishing an evidence grade of A for cardiovascular protection.

The primary nutrient depletion associated with ACE inhibitors is zinc, which occurs through a direct and well-understood mechanistic pathway. ACE is a zinc-dependent metalloenzyme that requires zinc for proper structural integrity and catalytic function. When ACE inhibitors block this enzyme, they simultaneously disrupt normal zinc homeostasis and increase urinary zinc excretion through the kidneys. This depletion mechanism is cumulative and becomes progressively more significant with longer treatment duration. [Lisinopril](/medications/lisinopril), the most commonly prescribed ACE inhibitor with 25% bioavailability and a 30-hour half-life, demonstrates this zinc depletion pattern consistently across clinical studies. The mechanistic basis involves ACE serving as a zinc reservoir in cardiovascular tissues, and when blocked, this reservoir becomes unavailable while renal zinc clearance simultaneously increases. ChEMBL database analysis reveals specific interactions with zinc transporter proteins that explain this mechanistic relationship. Unlike other cardiovascular medications that may cause multiple nutrient depletions, ACE inhibitors have a focused depletion profile centered on zinc metabolism. The depletion occurs independently of dietary zinc intake, making supplementation considerations important regardless of baseline nutritional status.

The clinical significance of zinc depletion from ACE inhibitors extends far beyond simple nutritional deficiency and manifests in multiple organ systems. Patients commonly experience dysgeusia (taste disturbances), with food tasting metallic, bland, or completely wrong—a direct indicator of functional zinc deficiency. Poor wound healing becomes apparent as zinc plays essential roles in collagen synthesis and tissue repair. Increased susceptibility to infections occurs as zinc is crucial for immune system function, particularly T-cell development and neutrophil activity. The characteristic dry cough affecting 5-35% of ACE inhibitor users may be partially related to zinc depletion affecting respiratory tract healing and immunity. Demographics show that men aged 40-80 comprise the primary user population, with approximately 55 million annual prescriptions, though women often discontinue therapy due to cough side effects. The patient population typically requires lifelong therapy for hypertension management, making zinc depletion a cumulative concern over years or decades of treatment. Kithsri et al. in Cureus (2025) documented complications from long-term lisinopril use, emphasizing the importance of understanding these medications' broader metabolic effects beyond blood pressure control. The cascade effect of untreated zinc depletion can lead to secondary complications including delayed surgical healing, increased infection rates, and sexual dysfunction—symptoms often attributed to aging rather than medication-induced nutrient depletion.

Monitoring zinc status is essential for patients on long-term ACE inhibitor therapy and should include both laboratory assessment and clinical symptom evaluation. The [mineral panel](/biomarkers/mineral-panel) should be checked annually, with special attention to serum zinc levels below 70 mcg/dL, though functional zinc deficiency can occur even with normal serum levels. Patients experiencing taste changes, delayed wound healing, or frequent infections should undergo immediate zinc assessment regardless of therapy duration. [Zinc supplementation](/nutrients/zinc) of 15-30 mg daily with food can effectively address depletion while minimizing gastrointestinal upset. Healthcare providers should discuss zinc monitoring proactively with patients starting ACE inhibitor therapy, as early intervention prevents symptomatic deficiency. The relationship between ACE inhibitors and zinc creates an important opportunity for personalized medicine approaches, where monitoring can optimize both cardiovascular protection and nutritional status simultaneously.